EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET 2022-2028

Description

MARKET OUTLOOK

CRI’s study estimates the clinical trials support services market in Europe to grow with a CAGR of 8.15% during the forecast years 2022-2028. Italy, Spain, Germany, the United Kingdom, France, and Rest of Europe are analyzed in the market in this region.
Countries like Poland, Ireland, Austria, Switzerland, and others, are covered under Rest of Europe. In Poland, the number of clinical trials being performed has increased significantly. For instance, from 2000 to 2019, 1840 clinical trials took place in Poland. The increase in the number of trials also increases the amount of data generated. This calls for the adoption of support services such as data management, data processing, data analysis, etc. The increased use of support services is expected to drive the growth of the studied market in Poland, and, in turn, in Rest of Europe.
Spain ranks first in Europe and fourth in the world in terms of conducting clinical trials. The collaboration between the private and public sectors has contributed in making the country a leading name in the clinical trials sector. 1,019 trials were approved in 2020, of which 34% share was captured by medicines for treating various types of cancer. The major factor driving successful clinical trials is the involvement of an increasing number of patients in the trial process. For instance, in 2021, nearly 145,000 patients participated in more than 3,400 ongoing clinical trials in Spain.

COMPETITIVE OUTLOOK

The noteworthy players in the clinical trials support services market include IQVIA, ICON Plc, CTI Clinical Trial and Consulting Services Inc, Charles River Laboratories, PSI CRO, WuXi AppTec, Worldwide Clinical Trials, and Parexel.

TABLE OF CONTENTS

1. EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE CLINICAL TRIALS SUPPORT SERVICES MARKET
2.2. KEY INSIGHTS
2.2.1. KEY PLAYERS’ PROMISING COLLABORATIONS
2.2.2. INCREASE IN SCREENING TESTS
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. KEY BUYING IMPACT ANALYSIS
2.4.1. PERFORMANCE
2.4.2. EASE OF USE
2.4.3. SECURITY
2.4.4. COST EFFECTIVENESS
2.5. MARKET ATTRACTIVENESS INDEX
2.6. VENDOR SCORECARD
2.7. INDUSTRY COMPONENTS
2.8. REGULATORY FRAMEWORK
2.9. KEY MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT LAUNCHES
2.9.3. CONTRACTS & AGREEMENTS
2.9.4. INVESTMENTS & EXPANSIONS
2.10. MARKET DRIVERS
2.10.1. NEED TO OVERCOME THE BARRIERS IN CLINICAL TRIALS
2.10.2. RISE IN TRIALS DUE TO INCREASED DISEASE INCIDENCE
2.11. MARKET CHALLENGES
2.11.1. DELAYED APPROVAL DUE TO STRINGENT REGULATORY FRAMEWORK
2.11.2. USE OF OPEN-SOURCE SOFTWARE
2.12. MARKET OPPORTUNITIES
2.12.1. INCREASING DEMAND FOR VACCINES AND PHARMACEUTICALS
2.12.2. DATA MANAGEMENT SERVICE EXPECTED TO WITNESS NOTABLE GROWTH
2.12.3. ACQUISITIONS IN THE CLINICAL TRIALS SUPPORT SERVICES MARKET
3. EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET OUTLOOK – BY PHASE TYPE
3.1. PHASE I
3.2. PHASE II
3.3. PHASE III
3.4. PHASE IV
4. EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET OUTLOOK – BY SERVICE
4.1. CLINICAL TRIAL SITE MANAGEMENT
4.2. ADMINISTRATIVE SERVICES
4.3. PATIENT RECRUITMENT MANAGEMENT
4.4. REGULATORY SERVICES
4.5. DATA MANAGEMENT
4.6. OTHER SERVICES
5. EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET OUTLOOK – BY SPONSOR
5.1. PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
5.2. MEDICAL DEVICE COMPANIES
5.3. OTHER SPONSORS
6. EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET – COUNTRY OUTLOOK
6.1. UNITED KINGDOM
6.2. GERMANY
6.3. FRANCE
6.4. SPAIN
6.5. ITALY
6.6. REST OF EUROPE
7. COMPETITIVE LANDSCAPE
7.1. IQVIA
7.2. PAREXEL
7.3. ICON PLC
7.4. SYNEOS HEALTH
7.5. LABCORP DRUG DEVELOPMENT
7.6. CLINIPACE
7.7. KCR
7.8. CHARLES RIVER LABORATORIES
7.9. MEDPACE
7.10. ALCURA
7.11. PSI CRO
7.12. WORLDWIDE CLINICAL TRIALS
7.13. CTI CLINICAL TRIAL AND CONSULTING SERVICES INC
7.14. WUXI APPTEC
7.15. ADVANCED CLINICAL
8. RESEARCH METHODOLOGY & SCOPE
8.1. RESEARCH SCOPE & DELIVERABLES
8.2. SOURCES OF DATA
8.3. RESEARCH METHODOLOGY

TABLE LIST

TABLE 1: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: LIST OF COLLABORATIONS
TABLE 3: VENDOR SCORECARD
TABLE 4: REGULATORY FRAMEWORK
TABLE 5: LIST OF ACQUISITIONS
TABLE 6: LIST OF PRODUCT LAUNCHES
TABLE 7: LIST OF CONTRACTS & AGREEMENTS
TABLE 8: LIST OF INVESTMENTS & BUSINESS EXPANSIONS
TABLE 9: LIST OF PANDEMIC OUTBREAKS
TABLE 10: LIST OF OPEN-SOURCE SOFTWARE
TABLE 11: LAUNCH OF MEDICAL DRUGS
TABLE 12: PROMISING ACQUISITIONS IN THE MARKET
TABLE 13: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SERVICE, 2022-2028 (IN $ MILLION)
TABLE 14: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE TYPE, 2022-2028 (IN $ MILLION)
TABLE 15: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SPONSOR, 2022-2028 (IN $ MILLION)
TABLE 16: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

FIGURE LIST

FIGURE 1: KEY BUYING IMPACT ANALYSIS
FIGURE 2: MARKET ATTRACTIVENESS INDEX
FIGURE 3: INDUSTRY COMPONENTS
FIGURE 4: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE TYPE, 2021 & 2028 (IN %)
FIGURE 5: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE I, 2022-2028 (IN $ MILLION)
FIGURE 6: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE II, 2022-2028 (IN $ MILLION)
FIGURE 7: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE III, 2022-2028 (IN $ MILLION)
FIGURE 8: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHASE IV, 2022-2028 (IN $ MILLION)
FIGURE 9: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SERVICE, 2021 & 2028 (IN %)
FIGURE 10: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY CLINICAL TRIAL SITE MANAGEMENT, 2022-2028 (IN $ MILLION)
FIGURE 11: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY ADMINISTRATIVE SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 12: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PATIENT RECRUITMENT MANAGEMENT, 2022-2028 (IN $ MILLION)
FIGURE 13: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY REGULATORY SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 14: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY DATA MANAGEMENT, 2022-2028 (IN $ MILLION)
FIGURE 15: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY OTHER SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 16: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY SPONSOR, 2021 & 2028 (IN %)
FIGURE 17: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY MEDICAL DEVICE COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 19: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, BY OTHER SPONSORS, 2022-2028 (IN $ MILLION)
FIGURE 20: EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 21: UNITED KINGDOM CLINICAL TRIALS SUPPORT SERVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 22: GERMANY CLINICAL TRIALS SUPPORT SERVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 23: FRANCE CLINICAL TRIALS SUPPORT SERVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 24: SPAIN CLINICAL TRIALS SUPPORT SERVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: ITALY CLINICAL TRIALS SUPPORT SERVICES MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: REST OF EUROPE CLINICAL TRIALS SUPPORT SERVICES MARKET 2022-2028 (IN $ MILLION)